A new paper in the journal Nature reveals an astonishing—and frankly unsettling—feature of some cancer cells: the ability to physically inject mitochondria into their neighboring cells. These ...

Cancer cells can brainwash their neighbors. Like the CIA deploying secret agents to turn an enemy, tumors use a similar strategy to manipulate nearby cells. The tumors’ agents are mitochondria, the ...

Rheumatoid arthritis (RA) is characterized by high morbidity, disability, and mortality rates and is intricately linked to metabolic reprogramming that governs immune cell dysfunction and inflammatory ...

RNA-LNP Based, Non-Viral Delivery - RNA-LNP delivery avoids genome integration risks, leaving no genetic footprint. Optimized for PBMCs - The only non-viral kit proven effective for PBMC reprogramming ...

Details of a new drug that aims to treat the underlying causes of obesity were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 ...

The rise of robotics and AI is transforming Asia’s industrial landscape, with China, Japan and South Korea leading adoption. While automation may reinforce regional trade, it also poses reshoring ...

In a Cambridge lab, a team of scientists may have found a new way to fight the most aggressive brain cancer—not by killing it, but by locking it in place. Glioblastoma, the deadliest and most common ...

The immune system can be "reprogrammed" to heal the body faster using electrical stimulation, according to new research. Irish scientists discovered that electrically stimulating “macrophages” – one ...

School of Pharmacy, Jiang Su Key Laboratory of Drug Design and Optimization, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China ...

According to Coherent Market Insights, the global Cell Reprogramming Market is estimated to be valued at USD 401.7 Mn in 2025 and is expected to reach USD 715.6 Mn by 2032, exhibiting a compound ...

This study reveals that PRMT1 overexpression drives tumorigenesis of acute megakaryocytic leukemia (AMKL) and that targeting PRMT1 is a viable approach for treating AMKL. After revision, both ...